CA-5f

Catalog No.S5920 Batch:S592001

Print

Technical Data

Formula

C24H24N2O3
Molecular Weight 388.46 CAS No. 1370032-19-1
Solubility (25°C)* In vitro DMSO 78 mg/mL (200.79 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description CA-5f is a potent late-stage macroautophagy/autophagy inhibitor via inhibiting autophagosome-lysosome fusion.
Targets
Autophagy [1]
In vitro CA-5f neither impairs the hydrolytic function nor the quantity of lysosomes. Treatment of human umbilical vein endothelial cells (HUVECs) with CA-5f for 1 h suppresses the levels of cytoskeletal proteins and membrane traffic proteins. CA-5f exhibits strong cytotoxicity against A549 non-small cell lung cancer (NSCLC) cells, but low cytotoxicity to normal human umbilical vein endothelial cells (HUVECs), by increasing mitochondrial-derived reactive oxygen species (ROS) production. CA-5f inhibits autophagic flux by blocking autophagosome-lysosome fusion instead of affecting the pH and hydrolytic function of lysosomes[1].
In vivo CA-5f effectively suppresses the growth of A549 lung cancer xenograft as a single agent with an excellent tolerance in vivo. It inhibits autophagic flux, induced apoptosis, and does not affect the level of CTSB (cathepsin B) and CTSD (cathepsin D) in vivo[1].

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    A549 cells or HUVECs

  • Concentrations

    20 μM

  • Incubation Time

    96 h

  • Method

    A549 cells or HUVECs are seeded into E-Plate 16-well plates overnight and then treated with DMSO or CA-5f and continuously monitored for 96 h. The changes of cell index can be used to monitor cell viability.
Animal Study:

[1]
  • Animal Models

    Four-week-old BALB/c nude mice (subcutaneous injection of A549 cells at the right scapula)

  • Dosages

    40 mg/kg

  • Administration

    injected via caudal vein

Selleck's CA-5f has been cited by 1 publication

Synergetic contributions of viral VP1, VP3, and 3C to activation of the AKT-AMPK-MAPK-MTOR signaling pathway for Seneca Valley virus-induced autophagy [ J Virol, 2021, JVI0155021] PubMed: 34757844

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.